Safety is the largest component the FDA analyses for, not exactly "orders of magnitude" less than efficacy.

Increasing the patent length, however, would increase the payback. Not as much as one might think, however, because the time-value-of-money analysis means that money far in the future is worth less, so there is diminishing returns at work.